Study of GS-5319 in Adults With Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumor
In brief
The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme helps in normal growth of cells. The primary objectives of the study are to assess the safety and tolerability of GS-5319 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors and to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended dose for expansion (RDE).
Key facts
- Study ID
- NCT07128303
- Run by
- Gilead Sciences
- People needed
- 178
- Starts
- 2025-08-28
- Expected to finish
- 2028-05-01
- Last updated by the study team
- 2026-06-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- START San Antonio — San Antonio, Texas, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- Yonsei University Severance Hospital — Seoul, South Korea (enrolling)
- Seoul National University Hospital — Seoul, South Korea (enrolling)
- Asan Medical Center — Seoul, South Korea (enrolling)
- Samsung Medical Center — Seoul, South Korea (enrolling)
- Vall d'Hebron Institute of Oncology (VHIO) — Barcelona, Spain (enrolling)
- START Madrid - FJD - Hospital Fundación Jiménez Díaz - Phase I Clinical Trials Unit — Madrid, Spain (enrolling)
- START - Centro Oncológico Clara Campal — Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.